Chinese Stocks Stumble Amid Beta Retreat: Alpha Emerges as New Market Driver

Diminishing Momentum in U.S.-Listed Chinese Stocks: The Ebb of Macro Beta, the Rise of Micro Alpha

The Nasdaq Golden Dragon China Index (HXC) rose 1.59% on Friday to close at 6,952.52—yet this seemingly positive late-session rally failed to reverse the index’s weekly decline. Data shows HXC fell 3.85% for the week—the steepest single-week drop in nearly a month. More telling are signals from ETFs: the KraneShares CSI China Internet ETF (KWEB) dropped 5.32% for the week; while the iShares U.S. Listed China Large-Cap ETF (CQQQ) edged up 1.69% on Friday, it ended its three-week consecutive rally and posted a 0.89% weekly decline. Similarly, the Deutsche X-trackers Harvest CSI 300 ETF (ASHR) and the Xtrackers Harvest CSI 50 ETF (ASHS) both halted their prior upward streaks and posted modest pullbacks. On the surface, this appears a technical correction—but beneath lies a quiet yet profound structural shift in the investment logic governing U.S.-listed Chinese stocks: a rapid transition from “beta-driven” strategies anchored in policy expectations and macro narratives, toward “alpha-driven” approaches focused on tangible execution capability and viable profit pathways.

Persistent Macro Constraints: Dual Pressure from U.S.–China Relations and Data Vacuums

This waning rebound momentum is no isolated event—it reflects the concentrated emergence of multiple macro constraints. First and foremost is the marginal shift in U.S.–China relations. Although no major confrontation has erupted recently, U.S. caution remains firmly entrenched across semiconductor equipment export controls, biotech investment reviews, and the pace of audit regulatory dialogue—prompting markets to reassess the stability of the so-called “policy bottom.” Compounding this is the Federal Reserve’s sustained high-interest-rate stance and the approaching U.S. presidential election cycle, which naturally heighten geopolitical sensitivity: even minor signals regarding technology decoupling or capital flow restrictions are readily amplified and interpreted as systemic risks.

Second, domestic economic data has entered a temporary “vacuum period.” While April’s PMI and social financing data have been released, key May macro indicators—including industrial output, retail sales, and property sales—have yet to be published en masse. With no anchor to validate the strength of the recovery, investor expectations around the scale and transmission efficiency of “stabilization” policies have become more rationalized—rendering unsustainable the broad-based, sentiment-fueled rallies seen earlier. Notably, major U.S. indices performed strongly during the same period: the S&P 500, Nasdaq Composite, and Nasdaq-100 all hit record highs, while the Philadelphia Semiconductor Index advanced for 18 consecutive trading days—NVIDIA surged 4.3% in a single day, and Intel soared 24%. This stark contrast underscores that U.S.-listed Chinese stocks face not systemic risk within the global tech sector, but rather their own distinct structural bottlenecks.

Deepening Structural Divergence: AI Applications, Intelligent Driving, and Innovative Drugs Form the “Triangle of Certainty”

Amid broad index pressure, individual stocks exhibited pronounced divergence. Baidu rose 5.9% for the week; XPeng Motors, Zai Lab, and GDS Holdings each gained over 4%; while CenturyLink, WeRide, and Alibaba posted gains of approximately 3%. This “index down, leaders up” divergence is a clear signal of active portfolio rebalancing: investors are systematically exiting broad-based thematic positions lacking earnings support—and instead concentrating capital in three sectors offering demonstrable commercialization pathways and strong potential for overseas validation—forming today’s most robust “Triangle of Certainty” among U.S.-listed Chinese stocks.

The first pillar is rapid commercialization of AI applications. Baidu’s strength is no coincidence. Its ERNIE Bot 4.5 large language model has achieved scalable deployment across enterprise (B2B) segments—including finance, government services, and manufacturing—with API call volume surging over 120% quarter-on-quarter. Simultaneously, the ERNIE Bot mobile app surpassed 10 million monthly active users, marking early success in consumer (B2C) monetization. This signals China’s AI industry has moved beyond the “technology demonstration” phase into an “earnings realization” cycle. In contrast, AI-related stocks with purely conceptual appeal face mounting pressure.

The second pillar is commercial breakthroughs in intelligent driving. XPeng’s XNGP urban navigation-assisted driving system is now live in 243 Chinese cities; its NOP+ feature boasts a user penetration rate exceeding 75%, and is already generating stable recurring revenue via subscription services. According to company financial disclosures, intelligent driving software revenue accounts for 8.3% of total vehicle revenue—and carries significantly higher gross margins than hardware sales. This “hardware-first, software-monetization” model provides the market with a quantifiable, repeatable profit framework.

The third pillar is globalization of innovative drugs. Zai Lab’s repotrectinib received accelerated FDA approval for ROS1-positive non-small cell lung cancer—the first targeted therapy developed and led by a Chinese biotech firm to gain U.S. approval. Meanwhile, Zejula (niraparib), co-developed with Zai Lab, has made progress in health insurance negotiations across multiple European countries, with overseas revenue now accounting for 42% of total revenue. These milestones dismantle the market’s long-held perception of Chinese biotechs as “R&D-heavy but commercialization-light,” proving domestic firms can fully participate in—and contribute meaningfully to—the global innovative drug value chain.

A Fundamental Shift in Investment Logic: From “Policy Arbitrage” to “Earnings Validation”

KWEB’s and CQQQ’s termination of consecutive rallies is far more than short-term volatility—it marks a pivotal inflection point in the valuation architecture of U.S.-listed Chinese stocks. For years, their price action was heavily driven by speculation on regulatory policy pivots—be it the “double reduction” education reforms, platform economy regulation, or data security reviews—each triggering index-level swings. Yet as the regulatory framework has largely crystallized, market focus inevitably shifts to the critical question: What happens after policy? At this stage, strategies predicated solely on betting on “easing expectations” have lost efficacy. Only companies capable of converting policy tailwinds into real revenue and profits will command sustained valuation premiums.

This paradigm shift brings three profound implications:
First, industry concentration accelerates. High-tech, highly regulated sectors—including AI, intelligent driving, and biopharma—exhibit intensified “Matthew effect”: rising technological barriers and compliance costs squeeze out smaller players.
Second, valuation methodologies evolve. Metrics like price-to-sales (P/S) ratios and user growth—once dominant in early-stage analysis—are losing weight; instead, forward-looking indicators such as free cash flow (FCF), R&D conversion efficiency, and overseas clinical trial timelines gain prominence.
Third, investor composition improves. Passive, broad-based ETF inflows slow, while active thematic funds, hedge funds, and strategic industrial capital increase allocations—driving deeper research and longer holding periods.

Outlook: Divergence Is Evolution—The True Alpha Era Has Just Begun

The near-term softness in U.S.-listed Chinese stock indices should not be misread as systemic risk. Quite the contrary—it signals the market is maturing, applying more rigorous, rational filters to identify truly globally competitive Chinese enterprises. When the Golden Dragon Index’s movements are no longer dictated by a single macro variable, but instead steered by micro-level metrics—such as Baidu’s API call volume, XPeng’s intelligent driving subscription ARPU, or Zai Lab’s FDA approval timeline—the investment value of U.S.-listed Chinese stocks finally returns to its essence: not a bet on national destiny, but a disciplined identification of genuine excellence.

Over the next three months—amid the sequential release of China’s Q2 economic data, the possible resumption of high-level U.S.–China economic dialogues, and an increasing number of U.S.-listed Chinese firms entering earnings verification windows—structural divergence is poised to deepen further. For investors, the priority is no longer tracking index levels, but conducting deep-dive analysis across industry value chains—to identify alpha-generating names in niche domains such as AI compute infrastructure, full-stack intelligent driving solutions, and first-in-class innovative drug pipelines—where product-market fit, order visibility, and regulatory approvals have already validated underlying strength. After all, in the capital markets’ long arc, what endures across cycles is never grand narrative—but consistent, tangible delivery.